Chemoembolization in patients at high risk: Results and complications

Journal of Vascular and Interventional Radiology

Volumn 17, Issue 1, 2006, Pages 47-53

  Kiely, James M ^a   Rilling, William S ^a   Touzios, John G ^a   Hieb, Robert A ^a   Franco, Jose ^a   Saeian, Kia ^a   Quebbeman, Edward J ^a   Pitt, Henry A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTINEOPLASTIC AGENT; BILIRUBIN; CEFAZOLIN; CIPROFLOXACIN; CISPLATIN; DOXORUBICIN; ETHIODIZED OIL; METRONIDAZOLE; MITOMYCIN C; MOXIFLOXACIN; OCTREOTIDE;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER RISK; CANCER SURVIVAL; CHEMOEMBOLIZATION; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PORTAL VEIN; PRIORITY JOURNAL; PROGNOSIS; VEIN THROMBOSIS; AGED; EVALUATION; FOLLOW UP; HOSPITALIZATION; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; LIVER VEIN THROMBOSIS; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; HEPATIC VEIN THROMBOSIS; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33745301777     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000195074.43474.2F     Document Type: Article

References (23)

1. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37:429-442.
2. Falconi M, Bassi C, Bonora A, et al. Role of chemoembolization in synchronous liver metastases from pancreatic endocrine tumours. Dig Surg 1999; 16:32-38.
3. Kim YH, Ajani JA, Carrasco CH, et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 1999; 17:474-478.
4. Tellez C, Benson AB 3rd, Lyster MT, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998; 82:1250-1259.
5. Rajan DK, Soulen MC, Clark TW, et al. Sarcomas metastatic to the liver: Response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol 2001; 12:187-93.
6. Majno PE, Adam R, Bismuth H, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226:688-701.
7. Lu CD, Peng SY, Jiang XC, et al. Preoperative transcatheter arterial chemoembolization and prognosis of patients with hepatocellular carcinomas: Retrospective analysis of 120 cases. World J Surg 1999; 23:293-300.
8. Harnois DM, Steers J, Andrews JC, et al. Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma. Liver Transpl Surg 1999; 5:192-199.
9. Chung JW, Park JH, Han JK, et al. Hepatic tumors: Predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996; 198:33-40.
10. Lladó L, Virgili J, Figueras J, et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000; 88:50-57.
11. Kim HK, Chung YH, Song BC, et al. Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma. J Clin Gastroenterol 2001; 32:423-427.
12. Bruix J, Llovet JM. Prognostic assessment and evaluation of the benefits of treatment. J Clin Gastroenterol. 2002; 35(5 suppl 2): S138-S142.
13. Chan AO, Yuen MF, Hui CK, et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002; 94:1747-1752.
14. Sakamoto I, Iwanaga S, Nagaoki K, et al. Intrahepatic biloma formation (bile duct necrosis) after transcatheter arterial chemoembolization. AJR Am J Roentgenol 2003; 181:79-87.
15. Song SY, Chung JW, Han JK, et al. Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 2001; 12:313-320.
16. Poon RT, Ngan H, Lo CM, et al. Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol 2000; 73: 109-114.
17. Pentecost MJ, Daniels JR, Teltelbaum GP, et al. Hepatic chemoembolization: safety with portal vein thrombosis. J Vasc Interv Radiol 1993; 4:347-351.
18. Lee HS, Kim JS, ChoiI J, et al. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer 1997; 79:2087-2094.
19. Fan J, Wu ZQ, Tang ZY, et al. Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein. World J Gastroenterol 2001; 7:28-32.
20. Tazawa J, Maeda M, Sakai Y, et al. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 2001; 16:660-665.
21. Lygidakis NJ, Tsliakos S. Multidisciplinary management of hepatocellular carcinoma. Hepatogastroenterology 1996; 93:1611-1619.
22. Tang ZY, Uy YQ, Zhou XD, et al. Cytoreduction and segmental resection for surgically verified unresectable hepatocellular carcinoma: Evaluation with analysis of 72 patients. World J Surg 1995; 19:784-789.
23. Yu YQ, Xu DB, Zhou XD, et al. Experience with liver resection after hepatic arterial chemoembolization for hepatocellular carcinoma. Cancer 1993; 71:62-65.